Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma

Franco Di Filippo, F. Cavaliere, M. Anzà, R. Garinei, C. Botti, P. Perri, P. Di Angelo, V. Patrizi, S. Di Filippo, P. Visca

Research output: Contribution to journalArticle

Abstract

Liposome-containing doxorubicin has been employed in the treatment of advanced soft tissue limb sarcoma during hyperthermic perfusion. A phase I-II study was carried out starting with a standard dose of 10 mg//L of limb volume, the dosage was escalated with 2 mg for each triplet of patients. The maximum tolerable (MTD) dose was established as the amount able to cause a grade IV limb reaction at least in two out of three patients, the temperature level remained unchanged (41.5°C). The grade of limb reaction ranged between I-II (mild edema and erythema). Only in two patients treated with 18 mg/L of limb volume was a grade IV limb reaction observed, therefore MTD at a temperature of 41.5°C is 16 mg. A good tumor response was observed in 29% of the patients, partial response in 71%. The tumor shrinkage after perfusion permitted conservative surgery in 91% of the cases.

Original languageEnglish
Pages (from-to)66-69
Number of pages4
JournalJournal of Chemotherapy
Volume16
Issue numberSUPPL. 5
Publication statusPublished - Nov 2004

Keywords

  • Doxorubicin
  • Liposomal doxorubicin
  • Soft tissue limb sarcoma
  • TNFα

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma'. Together they form a unique fingerprint.

  • Cite this

    Di Filippo, F., Cavaliere, F., Anzà, M., Garinei, R., Botti, C., Perri, P., Di Angelo, P., Patrizi, V., Di Filippo, S., & Visca, P. (2004). Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma. Journal of Chemotherapy, 16(SUPPL. 5), 66-69.